| |
 |
AMA PRA Category 1 Credit(s)™
Release Date 12/6/2012
Expiration Date 12/31/2013 |
|
|
| |
|
|
| |
 |
Nezam Afdhal, MD
Beth Israel Deaconess
Medical Center
Boston, MA
|
|
| |
 |
|
| |
|
|
| |
 |
Kim Brown, MD
Henry Ford Hospital
Detroit, MI |
|
| |
|
|
| |
|
|
| |
 |
Jordan Feld, MD
Toronto Western Hospital
Liver Center
Toronto, Canada |
|
| |
|
|
| |
|
|
| |
 |
Michael Fried, MD
University of North Carolina
Chapel Hill, NC |
|
| |
|
|
| |
|
|
| |
 |
Ira Jacobson, MD
Weill Cornell Medical College
New York, NY |
|
| |
|
|
| |
|
|
| |
|
|
| |
 |
|
| |
|
|
| |
|
| |
|
|
|
|
|
Michael Fried, MD
University of North Carolina
Chapel Hill, NC |
Michael W. Fried, MD, is Professor of Medicine and Director of Hepatology at the University of North Carolina (UNC) at Chapel Hill. He completed his residency in internal medicine and fellowship in gastroenterology at the State University of New York (SUNY) Health Science Center at Syracuse.
Dr. Fried has performed clinical and laboratory studies of viral hepatitis since 1990, when he served for 3 years as a medical staff fellow in the Liver Diseases Section at the National Institutes of Health, Bethesda, Maryland. During his tenure at UNC, he has served as the principal investigator on numerous clinical trials of various antiviral agents for chronic hepatitis B and hepatitis C. Dr. Fried has received continuous NIH extramural funding for more than 10 years as principal investigator on several NIH cooperative clinical trials, including VIRAHEP-C (NIDDK), SYNCH-C (NCCAM), and the Hepatitis B Research Network (NIDDK). Dr. Fried is also a recipient of an NIH career development award (K24), which allows him to provide mentorship to junior investigators in hepatitis research.
Dr. Fried is the primary author or co-author on over 120 original publications, reviews, and book chapters concentrating on the field of viral hepatitis. He is a longstanding member of the American Association for the Study of Liver Diseases, where he was recently appointed to the Steering Committee of the newly created Special Interest Group for Hepatitis C. Dr. Fried has been inducted into the American Society of Clinical Investigation (ASCI), an honor society for clinical investigators.
Speaker Disclosure:
Michael Fried, MD, has disclosed that he has received grants for clinical research and grants for educational activities from Genentech/Roche, Merck, Vertex, Tibotec/Janssen, Gilead, Bristol Myers Squibb, Anadys, Conatus, and Abbott. He has served as a consultant for Genentech/Roche, Tibotec/Janssen, Vertex, Merck, Glaxo, Novartis, Abbott, Gilead, and Bristol Myers Squibb. Additionally, he has received other financial support for research grants from NIH.
|
|
